HomeCompareMEPDF vs ABBV

MEPDF vs ABBV: Dividend Comparison 2026

MEPDF yields 2.19% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MEPDF wins by $24.2K in total portfolio value· pulled ahead in Year 9
10 years
MEPDF
MEPDF
● Live price
2.19%
Share price
$19.00
Annual div
$0.42
5Y div CAGR
50.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$126.5K
Annual income
$49,895.16
Full MEPDF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MEPDF vs ABBV

📍 MEPDF pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMEPDFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MEPDF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MEPDF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MEPDF
Annual income on $10K today (after 15% tax)
$186.37/yr
After 10yr DRIP, annual income (after tax)
$42,410.89/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MEPDF beats the other by $21,354.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MEPDF + ABBV for your $10,000?

MEPDF: 50%ABBV: 50%
100% ABBV50/50100% MEPDF
Portfolio after 10yr
$114.4K
Annual income
$37,333.46/yr
Blended yield
32.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MEPDF
No analyst data
Altman Z
2.8
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MEPDF buys
0
ABBV buys
0
No recent congressional trades found for MEPDF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMEPDFABBV
Forward yield2.19%3.06%
Annual dividend / share$0.42$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR50.2%40.6%
Portfolio after 10y$126.5K$102.3K
Annual income after 10y$49,895.16$24,771.77
Total dividends collected$98.5K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MEPDF vs ABBV ($10,000, DRIP)

YearMEPDF PortfolioMEPDF Income/yrABBV PortfolioABBV Income/yrGap
1$11,029$329.33$11,550$430.00$521.00ABBV
2$12,311$509.88$13,472$627.96$1.2KABBV
3$13,972$798.93$15,906$926.08$1.9KABBV
4$16,223$1,272.78$19,071$1,382.55$2.8KABBV
5$19,433$2,074.47$23,302$2,095.81$3.9KABBV
6$24,281$3,488.22$29,150$3,237.93$4.9KABBV
7$32,099$6,118.23$37,536$5,121.41$5.4KABBV
8$45,700$11,353.62$50,079$8,338.38$4.4KABBV
9← crossover$71,589$22,690.29$69,753$14,065.80+$1.8KMEPDF
10$126,496$49,895.16$102,337$24,771.77+$24.2KMEPDF

MEPDF vs ABBV: Complete Analysis 2026

MEPDFStock

Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprises medical equipment and medical materials, and clinical diagnostic reagents for use from the pre-symptomatic stage; handles PMS services on contract for manufacturers; and invests in orphan drugs and other products. The company is also involved in the wholesale of cosmetics, daily necessities, and OTC pharmaceuticals; animal health products for companion animals; food processing raw materials for agriculture, fisheries, and livestock; and livestock feed additives, seasonings, veterinary medical equipment, packaging materials, industrial chemicals, and other products. In addition, it engages in the contract-based epidemiological studies, clinical studies, etc.; creation of a computerized medical supply database and master product databases for medical facilities; health insurance claims reviews, medical coding dispatch, outsourcing, and remote education activities; life and non-life insurance agency business; cleaning management; management and operation of distribution centers; commissioned delivery and worker dispatch business; and planning, management, administration, and product and service development for the class A health dispensing pharmacies service brand. Medipal Holdings Corporation serves hospitals, clinics, dispensing pharmacies, drugstores, home centers, convenience stores, supermarkets, discount stores, animal hospitals, livestock and fishery businesses, and processed food manufacturers. The company was formerly known as Mediceo Paltac Holdings Co., Ltd. and changed its name to Medipal Holdings Corporation in October 2009. Medipal Holdings Corporation was founded in 1898 and is headquartered in Tokyo, Japan.

Full MEPDF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MEPDF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MEPDF vs SCHDMEPDF vs JEPIMEPDF vs OMEPDF vs KOMEPDF vs MAINMEPDF vs JNJMEPDF vs MRKMEPDF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.